Douha Bannan

Dr. Douha Bannan


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Plants
Verified
Journal Article
Open access
PDF file
NFNouran M. Fahmy
Nouran M. Fahmy
Sameh S. ElhadySameh S. Elhady
Sameh S. Elhady
DBDouha Bannan
Douha Bannan
RMRania T. Malatani
Rania T. Malatani
HGHaidy A. Gad
Haidy A. Gad
The mass-based metabolomic approach was implemented using GC-MS coupled with chemometric analysis to discriminate between the essential oil compositions of six cultivars of Citrus reticulata. The antiaging capability of the essential oils were investigated through measurement of their ability to inhibit the major enzymes hyaluronidase, collagenase, and amylase involved in aging. GC-MS analysis resulted in the identification of thirty-nine compounds including β-pinene, d-limonene, γ-terpinene, linalool, and dimethyl anthranilate as the main components. Multivariate analysis using principal component analysis (PCA) and hierarchal cluster analysis (HCA) successfully discriminated the cultivars into five main groups. In vitro antiaging activity showed that Kishu mandarin (Km) (2.19 ± 0.10, 465.9 ± 23.7, 0.31 ± 0.01 µg/mL), Cara mandarin (Cm) (3.22 ± 0.14, 592.1 ± 30.1, 0.66 ± 0.03 µg/mL), and Wm (8.43 ± 0.38, 695.2 ± 35.4, 0.79 ± 0.04%) had the highest inhibitory activity against hyaluronidase, collagenase, and amylase, respectively. Molecular docking studies on the major compounds validated the activities of the essential oils and suggested their possible mechanisms of action. Based on our result, certain cultivars of Citrus reticulata can be proposed as a promising candidate in antiaging skin care products.

GAGhadah Assiri
Ghadah Assiri
DBDouha Bannan
Douha Bannan
GAGhadah Alshehri
Ghadah Alshehri
MAManal Alshyhani
Manal Alshyhani
WAWalaa Almatri
Walaa Almatri
Mansour A MahmoudMansour A Mahmoud
Mansour A Mahmoud
This study aimed to determine the estimated proportion of contraindications among women taking combined oral contraceptives (COCs) and to assess the risk factors associated with their contraindications. This study was cross-sectional. Reproductive-aged women (18–49 years) on any COCs between 2018 and 2020 were recruited from one obstetrics–gynaecology clinic in a university-affiliated hospital and were included. Contraindications were defined using the World Health Organization (WHO) Medical Eligibility Criteria (MEC) for Contraceptive Use. Data were collected from electronic medical records for all included women, as well as a standardised, pretested, structured survey for one-third of the women. In this cross-sectional study, 380 women using COCs were included. Their mean age was 31.645 ± 7.366 years. Among them, 131 (34.5%) participated via a survey and electronic records, while the other 249 (65.5%) participated via electronic records only. The majority of the participants had a Bachelor’s degree (59.0%) and were married (62.1%). The overall estimated proportion of patients with at least one contraindication to COCs according to category 3 (relative contraindications) or 4 (absolute contraindications) was 31.3% (95% CI 26.63–35.99). The most common contraindications observed were controlled hypertension, category 3 (12.1%); major surgery with prolonged immobilisation, category 4 (4.7%); migraine with aura at any age, category 4 (4.2%); breastfeeding from six weeks to less than six months postpartum, category 3 (4.0%); and diabetes mellitus with complications, category 4 (3.2%). Significant factors associated with contraindications to COCs were married women (OR 2.19, 95% CI 1.38–3.46), those aged 35 years or more (OR 2.33, 95% CI 1.49–3.66), and those with one or more live births (OR 2.19, 95% CI 1.38–3.46). Ensuring proper assessment prior to prescribing and considering alternatives suitable for long-term use among women taking an oral contraceptive regularly is recommended.

1 May 2019 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
DBDouha Bannan
Douha Bannan
MAMohammed A. Aseeri
Mohammed A. Aseeri
AAAeshah AlAzmi
Aeshah AlAzmi
MTMary P. Tully
Mary P. Tully

DBDouha Bannan
Douha Bannan
NAnadeem ali
nadeem ali
NANabil A. Alhakamy
Nabil A. Alhakamy
MAMohamed Alfaleh
Mohamed Alfaleh
WAWaleed Alharbi
Waleed Alharbi
Malarvannan GovindanMalarvannan Govindan
Malarvannan Govindan
Children spend most of their daily time indoors. Many of the items used indoors, such as furniture, electronics, textile, and children toys, are treated with chemicals to provide longevity and fulfil the safety standards. However, many chemicals added to these products are released into the environment during leaching out from the treated products. Many studies have reported brominated flame retardants (BFRs) in indoor environments; however, few have focused on environments specified for young children. In this study, paired air (PM10) and dust samples were collected from the rooms (n = 30) of Saudi children. These samples were analyzed for different congeners of polybrominated diphenyl ethers (PBDEs) and three important alternative flame retardants using gas chromatography-mass spectrometry. Decabromodiphenyl ether (BDE 209) was the most important analyzed BFR in dust and PM10 samples with a median value of 3150 ng/g of dust and 75 pg/m3. This indicates the wider application of BDE 209 has implications for its occurrence, although its use has been regulated for specified uses since 2014. Among alternative BFRs, 2-Ethylhexyl-2,3,4,5-tetrabromobenzoate (TBB), Bis(2-ethylhexyl)-3,4,5,6-tetrabromophthalate (TBPH), and 1,2-Bis(2,4,6-tribromophenoxy)ethane (BTBPE) were found with a median levels of 10, 15 and 8 ng/g of dust, respectively. However, alternative BFRs were present in <50% of the PM10 samples. The calculated long term and daily exposures via indoor dust and PM10 of Saudi children from their rooms were well below the respective reference dose (RfD) values. Nonetheless, the study highlights BDE 209 at higher levels than previously reported from household dust in Saudi Arabia. The study warrants further extensive research to estimate the different classes of chemical exposure to children from their rooms.

1 October 2021 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
DBDouha Bannan
Douha Bannan
MAMohammed A. Aseeri
Mohammed A. Aseeri
AAAeshah AlAzmi
Aeshah AlAzmi
MTMary P. Tully
Mary P. Tully

18 March 2021 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
AMAmnah Mukhtar
Amnah Mukhtar
MSMurooj Shukry
Murooj Shukry
DBDouha Bannan
Douha Bannan
What is known and Objective During the coronavirus disease of 2019 (COVID‐19) pandemic, there were periods when patients were not able to collect their medications from the hospital. The purpose of this study is to report on our management of the handling and delivery of biological medications to patients during periods of lockdown in the Kingdom of Saudi Arabia (KSA). Methods A descriptive study conducted at our 380‐bed tertiary care hospital. Managing the delivery of the biological medications was organized in six phases: (1) taskforce development, (2) identification of the relevant biological medications, (3) identification of patients, (4) organization of transportation, (5) medication delivery/pickup and (6) locating patients with unidentified addresses. The study was approved by our hospital's Institutional Review Board. Results and discussion Biological medications were delivered to 1235/1373 (90%) patients. This included 1875/2036 (92%) prescriptions. 900 prescriptions were delivered to 570 patients living in 95 cities and villages across the kingdom. 141 patients received 183 prescribed oral biological medications and 477 patients received 787 prescribed parenteral biological medications delivered with temperature control. 224 parenteral biological medication were delivered by car to 116 patients living in less accessible cities in the west of the country. The car deliveries of parenteral biological medications required particularly careful handling, packaging and temperature control. Delivering biological medications to patients during the curfew was a unique experience. However, the approach we have used ensured safe access to medications under appropriate conditions. What is new and Conclusion Delivering biological medications to patients during the lockdown was challenging. With the possibility of a second wave of COVID‐19, hospitals should have a standardized process in‐place for delivering such medications.